From Surf Wiki (app.surf) — the open knowledge base
BAY 38-7271
Chemical compound
Chemical compound
| elimination_half-life =
Originally synthesized by chemist Wayne E. Kenney, BAY 38-7271 (KN 38-7271) is a drug which is a cannabinoid receptor agonist developed by Bayer AG. It has analgesic and neuroprotective effects and is used in scientific research, with proposed uses in the treatment of traumatic brain injury. It is a full agonist with around the same potency as CP 55,940 in animal studies, and has fairly high affinity for both CB1 and CB2 receptors, with Ki values of 2.91nM at CB1 and 4.24nM at CB2. It has been licensed to KeyNeurotek Pharmaceuticals for clinical development, and was in Phase II trials in 2008 but its development appears to have stopped.
References
References
- (2003). "BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury". CNS Drug Reviews.
- (October 2003). "Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271". Brain Research.
- (July 2002). "Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties". The Journal of Pharmacology and Experimental Therapeutics.
- (December 2002). "Discriminative stimulus effects of BAY 38-7271, a novel cannabinoid receptor agonist". European Journal of Pharmacology.
- [http://www.keyneurotek.de/englisch/pipeline_content.html Pipeline]
- [http://www.keyneurotek.de/englisch/pdf/Ende%20Phase%20I%20Stroke_%20en_final.pdf KeyNeurotek Pharmaceuticals AG Reports Positive Phase I Data of Its Cannabinoid Receptor-Agonist]
This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.
Ask Mako anything about BAY 38-7271 — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report